Allovista is a clinical genomics platform for multimodal MRD detection and longitudinal immune monitoring. Amplicon sequencing, RNA-seq, and mass spectrometry — one platform, cross-modal concordance, in your lab.
Every input type. Every disease. Longitudinal tracking from diagnosis through remission and beyond.
Targeted BCR/TCR amplicon panels from any major platform. V(D)J annotation, clonotype resolution, and MRD quantification at sensitivities down to 10-6.
Extract immune repertoire from bulk or single-cell RNA-seq. De novo CDR3 assembly from standard transcriptomic data — no dedicated immune panel required.
Import mass spec MRD results and correlate with sequencing-based clonotype data. Cross-modal concordance scoring gives the fullest picture of disease status.
MRD testing shouldn't be locked to a single assay. Amplicon sequencing, RNA-seq, and mass spectrometry each reveal different facets of a patient's disease — and the clinical picture is sharpest when you correlate signals across modalities over time.
Allovista brings multimodal MRD analysis in-house. Your instruments, your data, your reports. Track clonotype dynamics alongside mass spec MRD concordance, immune reconstitution, and treatment response — across hematologic malignancies, autoimmune conditions like MS, and beyond.
When MRD analysis lives in your lab, the bottleneck disappears.
Ship samples to a reference lab. Wait 7–14 days for results. Testing cadence limited by logistics and cost. Physicians order fewer tests than the science warrants because turnaround is too slow to inform real-time clinical decisions.
Run MRD analysis on your own sequencer, in your own lab. Results the same day. Physicians can order tests as often as the clinical picture demands — weekly during induction, monthly in surveillance — because the workflow is local and the marginal cost is low.
Decentralizing sequencing workflows means the treating physician — not a send-out lab's queue — controls when and how often a patient is tested. For diseases like multiple myeloma, where early detection of molecular relapse can change outcomes, that frequency matters. Allovista gives every lab with a sequencer the same analytical capability that today only exists at a handful of reference centers.
We're building toward a 2027 launch. Drop your email for early access and development updates.
No spam. Occasional updates on launch timeline and beta access.
Thanks — we'll be in touch.